



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



**ASSESSMENT OF SERUM ADROPIN LEVEL AS A RISK
FACTOR OF ISCHAEMIC HEART DISEASE IN TYPE 2
DIABETES MELLITUS CASES**

Thesis

*Submitted for partial fulfillment of Master Degree in Endocrinology
and Metabolism*

Presented by

Baher Emil Ibrahim

M.B. B.Ch

Supervised by

Prof. Dr. Khaled Mahmoud Makkoul

Professour of Internal Medicine and Endocrinology

Faculty of Medicine, Ain Shams University

Dr. Salah Hussein Elhalawany

Lecturer of Internal Medicine and Endocrinology

Faculty of Medicine, Ain Shams University

Dr. Hany Khairy Mansour

Lecturer of Internal Medicine and Endocrinology

Faculty of Medicine, Ain Shams University

Dr. Dina Ahmed Marwan

Lecturer of Internal Medicine and Endocrinology

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2021



تقييم مستوى هرمون الادرولين كعامل خطر لمرض نقص تروية القلب في حالات مرضى السكري من النوع الثاني

رسالة

توطئة للحصول علي درجة الماجستير في الغدد الصماء والايض

مقدمة من

الطبيب/ باهر إميل إبراهيم

بكالوريوس الطب و الجراحة

تحت إشراف

أ.د/ خالد محمود مقبول

أستاذ امراض الباطنه والغدد الصماء

كلية الطب- جامعة عين شمس

د/ صلاح حسين الحلواني

مدرس امراض الباطنه والغدد الصماء

كلية الطب- جامعة عين شمس

د/ هاني خيرى منصور

مدرس امراض الباطنه والغدد الصماء

كلية الطب- جامعة عين شمس

د/ دينا احمد مروان

مدرس امراض الباطنه والغدد الصماء

كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَدَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

First and foremost thanks to *ALLAH*, the Most Merciful.

*I wish to express my deep appreciation and sincere gratitude to **Prof. Dr. Khaled Mahmoud Makboul**, Professour Internal Medicine and Endocrinology, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience, advices and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his direct supervision.*

*I wish to express my great thanks and gratitude **Dr. Salah Hussein Elhalawany**, Lecturer of Internal Medicine and Endocrinology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Hany Khairy Mansour**, Lecturer of Internal Medicine and Endocrinology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Dina Ahmed Marwan**, Lecturer of Internal Medicine and Endocrinology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

Last and not least, I want to thank all my family, my colleagues,, for their valuable help and support.

Finally I would present all my appreciations to my patients without them, this work could not have been completed.

Contents

Title	Page
• List of Abbreviations	I
• List of Table	III
• List of Figures.....	5
• Introduction	1
• Aim of the work	3
• Review of literature.....	
Chapter (1):Diabetes Mellitus Type 2.....	4
Chapter (2): Adropin Hormone.....	31
Chapter (3): Relationship between Adropin ,T2DM and Ischaemic heart disease.....	52
• Patients and methods	70
• Results	89
• Discussion.....	109
• Summary	119
• Conclusions	122
• Recommendations	123
• References	124
• الملخص العربي	158

LIST OF ABBREVIATIONS

ADA	American diabetes association
Adr-Tg	Adropin-overexpressing transgenic mice
AGEs	Advanced glycation end products
AIDS	Acquired immunodeficiency syndrome
AMI	Acute myocardial infarction.
BMI	Body mass index
CAD	Coronary artery disease
CIMT	Carotid intima-media thickness
CPT1B	Carnitine palmitoyl transferase-1b
CSX	Cardiac syndrome x.
CT	Computed tomography
CVD	Cardiovascular disease
DAG	Diacylglycerol
DHAP	Dihydroxyacetone phosphate.
DIO	Diet-induced obesity
eNOS	Endothelial nitric oxide synthase
ERK1/2	Extracellular signal-regulated kinases 1/2
EPC	Endothelial progenitor cells
F-1,6-P	Fructose-1,6-bisphosphate
F-6-P	Fructose-6-phosphate
FAO	Fatty acid oxidation
G-3-P	Glycerol-3-phosphate
GA3P	Glyceraldehyde-3-phosphate
GDM	Gestational diabetes mellitus
GFAT	Glutamine: fructose-6-phosphate amidotransferase
GIP	Glucose-dependent insulintropic polypeptide
GIPP	Gastric inhibitory polypeptide
GlcNAc	N-acetyl glucosamine
GLP-1	Glucagon like peptide-1
GPR19	G protein-coupled receptor
HDL	High density lipoprotein
HIV	Human immunodeficiency virus
HMGA1	High mobility group a1
HOMA-IR	The homeostatic model assessment of insulin resistance
IFG	Impaired fasting glucose
IGT	Impaired glucose tolerance
INSR	Insulin receptor gene
IRS1, IRS2	Insulin receptor substrate 1&2 ,

List of Abbreviations

MAPK1	Mitogen-activated protein kinase 1
MESA	Multi-ethnic study of atherosclerosis
MetS	Metabolic syndrome
MGO	Methylglyoxal
NAFLD	Non alcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
NICE	National institute for health and care excellence
NO	Nitric oxide.
OGTT	Oral glucose tolerance test
ORF	Open reading frame's
PAD	Peripheral arterial disease
PAI-1	Plasminogen activator inhibitor-1
PCOS	Polycystic ovarian syndrome ,
PDH	Pyruvate dehydrogenase ,
PDK4	Pyruvate dehydrogenase kinase 4.
PPAR γ	Peroxisome proliferator-activated receptor- γ
PI3K	Phosphoinoside-3 kinase
PKC	Protein kinase-c
QTL	Quantitative trait loci
ROS	Reactive oxygen species
RNS	Reactive nitrogen species
SA	Subclinical atherosclerosis
SAP	Stable angina pectoris
SNPs	Single-nucleotide polymorphisms
T2D	Type 2 diabetes
TGF-1	Transforming growth factor 1
TNF- α	Tumor necrosis factor alpha
UDP-cNAc	Uridine diphosphate n-acetyl glucosamine
UAP	Unstable angina pectoris
VEGF	Vascular endothelial growth factor
WHO	World health organization

LIST OF TABLE

Table No	Subjects	Page
Table (1):	Criteria for testing for diabetes or prediabetes in asymptomatic adults	10
Table (2):	Criteria defining prediabetes	10
Table (3):	Criteria for the diagnosis of diabetes.....	11
Table (4):	The concentration of adropin in biological materials	34
Table (5):	Demographic data of Group 1 (Diabetics with IHD).	90
Table (6):	Laboratory and radiological data of Group 1 (Diabetics with IHD):.....	91
Table (7):	Demographic data of Group 2 (Diabetics without IHD):	92
Table (8):	Laboratory and radiological data of Group 2 (Diabetics without IHD):.....	93
Table (9):	Demographic data of Group 3 (control group):.....	94
Table (10):	Laboratory and radiological data of Group 3 (control group):	94
Table (11):	Comparison between studied groups as regard hypertension and sex	95
Table (12):	Comparison between studied groups as regard age and body mass index.....	97
Table (13):	Comparison between studied groups as regard fasting glucose and insulin and post prandial glucose.....	99
Table (14):	Comparison between studied groups as regard laboratory parameters	102
Table (15):	Comparison between studied groups as regard carotid intima media thickness	103
Table (16):	Comparison between studied groups as regard adropin hormone level.....	104
Table (17):	Correlations between patients groups as regard adropin level.....	105

List of Table

Table No	Subjects	Page
Table (18):	Validity of adropin among diabetics with IHD and control.....	107
Table (19)	Validity of adropin among diabetics without IHD and control.....	108

LIST OF FIGURES

Figure No	Subjects	Page
Figure (1):	Pathophysiology of type 2 diabetes mellitus	6
Figure (2):	Pathophysiological effects of the polyol pathway.....	12
Figure (3):	Hexosamine pathway	14
Figure (4):	Protein kinase C role in Diabetes mellitus.	16
Figure (5):	Pathogenesis of diabetic complications via several potential mechanisms	17
Figure (6):	Glucose oxidation pathway	20
Figure (7):	Pathogenesis of diabetic nephropathy	26
Figure (8):	PKC in diabetic retinopathy	27
Figure (9):	Adropin structure.....	32
Figure (10):	Adropin in tissues and body fluids	34
Figure (11):	Effects of adropin	36
Figure (12):	Adropin and NASH progression	40
Figure (13):	Adropin levels & Endothelial cell activation	41
Figure (14):	Adropin signaling pathway in endothelium	43
Figure (15):	Potential roles of adropin	44
Figure (16):	Adropin effects.....	47
Figure (17):	Carotid intima media thickness	58
Figure (18):	Pathophysiological events leading to vascular complications in T2DM patients	61
Figure (19):	Endothelial dysfunction in diabetes: Hyperglycemia leads to increase production of ROS and RNS resulting oxidative stress. Oxidative stress	64
Figure (20):	Insulin Resistance and Endothelial Dysfunction.....	69
Figure (21):	Comparison between studied groups as regard sex.....	97
Figure (22):	Comparison between studied groups as regard Hypertension	97
Figure (23):	Comparison between studied groups as regard age	98
Figure (24):	Comparison between studied groups as regard body mass index.	99

Figure No	Subjects	Page
Figure (25):	Comparison between studied groups as regard glycated hemoglobin.	101
Figure (26):	Comparison between studied groups as regard insulin resistance.	102
Figure (27):	Comparison between studied groups as regard carotid intima media thickness	104
Figure (28):	Comparison between studied groups as adropin level	105
Figure (29):	Correlation between carotid intima media thickness and adropin concentration within diabetic without IHD group.....	107
Figure (30):	Correlation between fasting insulin and adropin concentration within diabetic without IHD group.....	107
Figure (31):	ROC curve between diabetic with IHD group and control.....	108
Figure (32):	ROC curve between diabetic without IHD group and control.....	109

INTRODUCTION

Type 2 diabetes was referred to as “noninsulin-dependent diabetes” accounts for 90–95% of all diabetes. This form includes individuals who have relative insulin deficiency and have peripheral insulin resistance. At least initially, and usually throughout their lifetime, these individuals may not need insulin treatment to survive (**ADA**., **2019**)

Diabetes Mellitus is the most frequent endocrine disease in developed countries estimated to have affected 366 million people worldwide and is expected to nearly double by 2030 owing to an increase in obesity, life span extension, and better detection of the disease. (**Gupta et al.**, **2014**).

It is widely accepted that in DM there is an impairment of endothelial nitric oxide synthase (eNOS) activity as well as enhancement of production of reactive oxygen species (ROS), resulting in diminished nitric oxide (NO) bioavailability and the consequent vascular alterations (**Tousoulis et al.**, **2012**)

DM has many ways of leading to endothelial dysfunction. The increased oxidative stress, the alteration of lipogenesis, the reduction of nitric oxide, and the alteration of endothelial progenitor cells (EPC) function create what is called the diabetic state, in which the